TIMING OF LEUKOCYTE FILTRATION DURING CARDIAC SURGERY

1999 ◽  
Vol 88 (Supplement) ◽  
pp. 15SCA
Author(s):  
AJ de Vries ◽  
YJ Gu ◽  
W van Oeveren
1999 ◽  
Vol 20 (3) ◽  
pp. 151-165 ◽  
Author(s):  
J.J.J Smit ◽  
A.J de Vries ◽  
Y.J Gu ◽  
W van Oeveren

ASAIO Journal ◽  
2007 ◽  
Vol 53 (4) ◽  
pp. 514-521 ◽  
Author(s):  
Oliver Warren ◽  
Sophie Wallace ◽  
Rachel Massey ◽  
Caroline Tunnicliffe ◽  
Christos Alexiou ◽  
...  

2013 ◽  
Vol 15 (5) ◽  
pp. 414-417 ◽  
Author(s):  
Hamidreza Taghipour ◽  
Hamid Shafiei ◽  
Omid Assar ◽  
Mohammad Saaid Ghiasi

2006 ◽  
Vol 54 (S 1) ◽  
Author(s):  
A Simon ◽  
M Scholz ◽  
S Martens ◽  
T Aybek ◽  
G Wimmer-Greinecker ◽  
...  

Perfusion ◽  
2005 ◽  
Vol 20 (5) ◽  
pp. 237-241 ◽  
Author(s):  
D Belway ◽  
F D Rubens ◽  
D Wozny ◽  
B Henley ◽  
H J Nathan

Introduction: Despite major advances in biomaterial research and blood conservation, bleeding is still a common complication after cardiopulmonary bypass and cardiac surgery remains a major consumer of blood products. Although the underlying mechanisms for these effects are not fully established, two proposed major etiologies are the hemodilution associated with the use of the heart-lung machine and the impact of reinfusion of shed cardiotomy blood. Therapeutic strategies that primarily encompass the use of devices or technologies to overcome these effects may result in improved clinical outcomes. Objective: To determine the extent to which 1) lipid/leukocyte filtration and centrifugal processing of cardiotomy blood, and 2) modified ultrafiltration (MUF) are currently applied in adult cardiac surgery in Canada. Methods: A questionnaire was mailed to the chief perfusionist at all adult cardiac surgical centers in Canada, addressing details regarding the frequency of use of cardiotomy blood processing and MUF. Results: All questionnaires (36, 100%) were completed and returned. With regards to cardiotomy blood management, in 21 centers (58%), no specific processing steps were utilized exclusive of the integrated cardiotomy reservoir filter. Of the remaining centers, two (6%) reported using lipid/leukocyte filtration and 15 (42%) reported washing their cardiotomy blood. Three centers (8%) reported using MUF at the end of CPB. Conclusions: Despite growing concern about the potential detrimental effects of cardiotomy blood, few centers in Canada routinely manage this blood with additional filtration and/or centrifugal processing prior to reinfusion. Similarly, MUF, demonstrated to be effective in the pediatric population, has not seen popular application in adult cardiac surgical practice.


2007 ◽  
Vol 31 (4) ◽  
pp. 665-676 ◽  
Author(s):  
Oliver Warren ◽  
Christos Alexiou ◽  
Rachel Massey ◽  
Daniel Leff ◽  
Sanjay Purkayastha ◽  
...  

2002 ◽  
Vol 51 (7) ◽  
pp. 363-368 ◽  
Author(s):  
M. Scholz ◽  
A. Simon ◽  
G. Matheis ◽  
O. Dzemali ◽  
D. Henrich ◽  
...  

Perfusion ◽  
2001 ◽  
Vol 16 (5) ◽  
pp. 361-370 ◽  
Author(s):  
G Matheis ◽  
M Scholz ◽  
A Simon ◽  
Omer Dzemali ◽  
A Moritz

Leukocyte filtration has evolved as an important technique in cardiac surgery with cardiopulmonary bypass to prevent pathogenic effector functions mediated by activated leukocytes. The underlying mechanisms that result in an improvement of laboratory variables as well as clinical outcome are not resolved yet. Moreover, the optimum strategy for the use of current filtration technology has not been systematically evaluated. This paper, therefore, reviews how activated leukocytes may lead to tissue damage, summarizes the known effects of leukocyte filtration on clinical outcome and laboratory parameters, and deals with current experimental and clinical efforts to further limit the pathogenic effects of leukocytes in cardiac surgery.


JAMA ◽  
1966 ◽  
Vol 195 (5) ◽  
pp. 356-361 ◽  
Author(s):  
J. B. McClenahan
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document